Surgical Treatment of Gynecomastia in the Body Builder

Aiache, Adrien E.

doi:10.1097/00006534-198901000-00011

Cited by 50 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These residual deformities may also cause psychologic distress to the patient. Good results have been reported in treating grade III gynecomastia with SAL Ϯ excision of any remaining breast parenchyma 12,20,21 (Fig. 6).…”

Section: Discussionmentioning

confidence: 99%

Gynecomastia

Wiesman

Lehman

Parker

et al. 2004

Annals of Plastic Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Gynecomastia

Wiesman

Lehman

Parker

et al. 2004

Annals of Plastic Surgery

View full text Add to dashboard Cite

show abstract

“…All had been treated with oxandrolone 0.25 mg/kg/day for 6 months to 8 and after therapy was completed in 14 subjects. Ingestion of drugs known to cause gynecomastia was ruled out.…”

Section: Methodsmentioning

confidence: 99%

Late Onset Gynecomastia Associated with Oxandrolone Therapy in Adolescents with Short Stature

Moore¹,

Ruvalcaba²

1991

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

Thirty-three males who had received oxandrolone therapy for short stature were evaluated for gynecomastia which had its onset during or following completion of therapy. When compared with a group of treated boys who did not develop gynecomastia, mean duration of treatment was similar (3.3 v. 3.4 yr), and appeared to have no relationship to the appearance of gynecomastia. When compared with a group of normal untreated males with transient gynecomastia, the subjects' mean age (16.1 v. 13.6 yr), mean bone age (14.7 v. 12.8 yr) and mean pubertal stage (4.2 v. 2.9) at onset were significantly greater. Ten of the 33 had transient gynecomastia and 23 had persistent gynecomastia which required mastectomy. Mean age, bone age, pubertal stage and duration of treatment were not different between these two groups. Mean breast size was significantly different (1.6 v. 6.4 cm) and was similar to that observed in two untreated groups with transient (1.7 cm) or persistent (6.9 cm) gynecomastia, with the exception that the untreated subjects tended to be younger and in an earlier pubertal stage at onset. We conclude that oxandrolone may delay appearance of gynecomastia and that if it occurs, it is more likely to be larger and persistent than typical adolescent gynecomastia. Patients receiving oxandrolone for growth stimulation should be advised of this possibility.

show abstract

“…(4) These patients also regularly request hair removal on the pectoral area, thereby eliminating the usual camouflage of scars by the periareolar hair. Based on this observation, we rejected the use of periareolar, transareolomammilar, and submammary fold access.…”

Section: Historymentioning

confidence: 99%